






Advancing future therapeutics

from discovery to delivery

Prepared for **Firstname Lastname**
Month 00, 0000



Vision

Our vision is a world in which access to life-changing therapies transforms human health.


Mission

Our mission is to advance and accelerate therapeutics.





Supporting customers at every phase



Pall + Cytiva—Deep expertise and global scale

16 000

associates in
40+ countries



4

key hubs




> 4000

commercial
associates serving
100+ countries




36

manufacturing
sites




> 100

FlexFactory™ and
KUBio™ facilities




23

R&D and
innovation centers





96%

customer
satisfaction
for service




Applying Danaher Business System to continuously improve customer satisfaction

Technologies for research and discovery



Enabling researchers to investigate and develop life-changing therapeutics


Complete solutions for mAbs



Services and support

Majority of mAbs approved by the FDA in 2020 use Cytiva technologies in manufacture

Complete solutions for mRNA



Pall Life Sciences and Cytiva technology used in majority of approved mRNA vaccines


Complete solutions for viral vectors




Research & Drug discovery




AAV Cell line development




Cell culture seed train and production



Clarification




TFF 1




Capture




Polishing



TFF Formulation



Sterile filtration



Fill-finish




Services and support

Pall Life Sciences and Cytiva technology used in majority of approved gene therapies



Complete solutions for cell therapies



Services and support

6 out of 7 approved CAR T cell therapies include Cytiva solutions

Innovating to support future therapeutics



Allegro™ Connect systems




AAV cell line development



ÄKTA oligosynt™



VIA Capsule™



Mechanistic modeling



Products

Services

Collaborations

Delivering on sustainability targets

Reducing carbon emissions

35%

absolute reduction in CO₂e emissions to include 100% renewable electricity by 2025

Evolving plastics and packaging

100%

- elimination of Styrofoam (polystyrene) by 2025
- single use plastics accepted for recycling by 2030

Responsible sourcing


85%

suppliers rated by EcoVadis by 2030

Design for sustainability

100%

of new products integrating sustainability into design since 2022



Learn more at
cytiva.com/sustainability




Part of Danaher: a focused science and technology leader










Face your
challenges
together
with **Cytiva**.



Let's keep in touch

-  facebook.com/cytiva
-  linkedin.com/company/cytiva
-  instagram.com/cytiva
-  twitter.com/cytiva
-  youtube.com/c/cytiva

Firstname Lastname

emailaddress@cytiva.com

0.000.000.0000



www.cytiva.com

Cytiva and the Drop logo are trademarks of Life Sciences IP Holdings Corp. or an affiliate doing business as Cytiva.

ÅKTA oligosynt, Allegro, FlexFactory, KUBio, and VIA Capsule are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

Pall and  are trademarks of Pall Corporation. ® Indicates a trademark registered in the USA.

All other third-party trademarks are the property of their respective owners.

Any use of software may be subject to one or more end user license agreements, a copy of, or notice of which, are available on request.

© 2023 Cytiva

For local office contact information, visit cytiva.com/contact